At week @ , the mean increase from baseline in FEV@ was @ ml greater in patients receiving intravenous mepolizumab than in those receiving placebo ( P = @ ) and @ ml greater in patients receiving subcutaneous mepolizumab than in those receiving placebo ( P = @ ) .